CURRENT LIQUID BIOPSY PUBLICATIONS
- 2025
- 2024
- 2023
- 2022
- 2021
-
2025
de Jager, V. D., et al. Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop. EBioMedicine, 114, 105636. 2025. https://doi.org/10.1016/j.ebiom.2025.105636
Pantel, K., Alix-Panabières, C. Minimal residual disease as a target for liquid biopsy in patients with solid tumours. Nat Rev Clin Oncol 22, 65–77, 2025; https://doi.org/10.1038/s41571-024-00967-y
Alix-Panabières, C., Pantel, K., Advances in liquid biopsy: From exploration to practical application, Cancer Cell, Volume 43, Issue 2, 2025, Pages 161-165, ISSN 1535-6108; https://doi.org/10.1016/j.ccell.2024.11.009
Pantel, K., et al. Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS). J Exp Clin Cancer Res 44, 156, 2025; https://doi.org/10.1186/s13046-025-03398-4
Ilié M, Malapelle U, Alix-Panabières C, Andersen CL, Chlebowski S, Lake V, Lacoux C, Lespinet-Fabre V, Bordone O, Heeke S, Bontoux C, Heitzer E, Pantel K, Hofman P. Perspectives in educating molecular pathologists on liquid biopsy: Toward integrative, equitable, and decentralized precision oncology. Mol Oncol. 2025 Nov 14. PMID: 41235697. Epub ahead of print. https://doi.org/10.1002/1878-0261.70163
-
2024
Mark Sementsov et. al. - Mutation analysis in individual circulating tumor cells depicts intratumor heterogeneity in melanoma; EMBO Mol Med, 2024, 16, 1560 - 1578; https://doi.org/10.1038/s44321-024-00082-6
Tanja Fehm et. al. - Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial; Clinical Chemistry, 2024, 70, 1, 307-318; https://doi.org/10.1093/clinchem/hvad144
Richard Drexler et. al. - A prognostic neural epigenetic signature in high-grade glioma; Nature Medicine, 2024, 30, 1622–1635; https://doi.org/10.1038/s41591-024-02969-w
-
2023
Paul van der Leest et al. – Detection and Monitoring of Tumor-Derived Mutations in Circulating Tumor DNA Using the UltraSEEK Lung Panel on the MassARRAY System in Metastatic Non-Small Cell Lung Cancer Patients; International Journal of Molecular Sciences, 2023, 24, 13390; https://doi.org/10.3390/ijms241713390 (Link zur Publikation: https://www.mdpi.com/1422-0067/24/17/13390 )
Heidrich et al. – Liquid biopsy for monitoring of tumor dormancy and early detection of disease recurrence in solid tumors; Cancer Metastasis Rev (2023). https://doi.org/10.1007/s10555-022-10075-x (Link zur Publikation: https://link.springer.com/article/10.1007/s10555-022-10075-x )
Wankhede et al. – Circulating Tumor Cells as a Predictive Biomarker in Resectable Lung Cancer: A Systematic Review and Meta-Analysis; Cancers 2022, 14(24), 6112; https://doi.org/10.3390/cancers14246112 (Link zur Publikation: https://www.mdpi.com/2072-6694/14/24/6112 )
-
2022
J. Pascual et. al. - ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group; Annals of Oncology, 2022, 33, 8, 750-768; https://doi.org/10.1016/j.annonc.2022.05.520 (Link zur Publikation: https://www.annalsofoncology.org/action/showPdf?pii=S0923-7534%2822%2901721-5
-
2021
Liquid Biopsy: From Discovery to Clinical Application
Interesting new review by ELBS pioneers Dr. Catherine Alix-Panabieres and Prof. Dr. med. Klaus Pantel on bridging the gap between state-of-the-art research and the clinical application of liquid biopsies.
cancerdiscovery.aacrjournals.org/content/11/4/858